Working… Menu

Plasma and Intrapulmonary Concentrations Study of WCK 5222

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03630094
Recruitment Status : Completed
First Posted : August 14, 2018
Last Update Posted : August 14, 2018
Information provided by (Responsible Party):

Brief Summary:
This is a Phase 1, multiple dose, open-label pharmacokinetic study in healthy adult male and female subjects.

Condition or disease Intervention/treatment Phase
PHA1A Drug: FEP-ZID Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 5222 (Cefepime and Zidebactam) in Healthy Adult Human Subjects
Actual Study Start Date : March 31, 2017
Actual Primary Completion Date : June 30, 2017
Actual Study Completion Date : July 30, 2017

Arm Intervention/treatment
Experimental: FEP-ZID via intravenous
total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen

Primary Outcome Measures :
  1. concentrations of cefepime (FEP) and zidebactam in epithelial lining fluid (ELF) [ Time Frame: Day 3 ]
  2. concentrations of cefepime (FEP) and zidebactam in alveolar macrophage (AM) [ Time Frame: Day 3 ]

Secondary Outcome Measures :
  1. Number of adverse event reported [ Time Frame: Day 3 ]
  2. number variation noted in 12-lead electrocardiogram [ Time Frame: Day 3 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body mass index (BMI) greater than or equal to18.5 and less than or equal to 30 (kg per m2) and weight between 55.0 and 100.0 kg (both inclusive).
  • Medical history without any major pathology as judged by the Investigator.
  • Forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value at screening.

Exclusion Criteria:

  • History or presence of significant oncologic, cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal,endocrine, immunologic, dermatologic, neurological, or psychiatric disease.
  • Positive alcohol breath test or urine drug screen test at screening or confinement.
  • Current use or has used tobacco or nicotine containing products 6 month prior to screening.
  • Positive testing for HIV, Hepatitis B or Hepatitis C.
  • History or presence of alcohol or drug abuse within the 2 years prior to screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03630094

Layout table for location information
United States, Arizona
Pulmonary Associates
Phoenix, Arizona, United States, 85006
Sponsors and Collaborators

Layout table for additonal information
Responsible Party: Wockhardt Identifier: NCT03630094     History of Changes
Other Study ID Numbers: W-5222-104
First Posted: August 14, 2018    Key Record Dates
Last Update Posted: August 14, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No